While the prognostic significance of the presence of CD38 on myeloblasts in acute myeloblastic leukemia (AML) in adults, and in multiple myeloma or chronic lymphocytic leukemia (CLL) is documented, the role of CD38 in BCP-ALL is unclear (9–17). This evidence concerns the gene CD38 and plasma cell myeloma.